#1939938
le haghaidh vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV)
for vaccines against SARS-related coronaviruses (SARS-CoV species)
Scag na torthaí
Bailiúcháin
278 toradh in 91 doiciméad
#2161765
Cód breise TARIC le haghaidh vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV)
Taric additional code for vaccines against SARS-related coronaviruses (SARS-CoV species)
#2542758
Vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV)
Vaccines against SARS-related coronaviruses (SARS-CoV species)
#2586437
Vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS “speicis SARS-CoV”, le haghaidh leigheas an duine
Vaccines against SARS-related coronaviruses ‘SARS-CoV species’, for human medicine
#3012856
Vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV)
Vaccines against SARS-related coronaviruses (SARS-CoV species)
#517464
Féadfar torthaí (Q)SARanna a úsáid in ionad tástála i gcás ina gcomhlíonfar na coinníollacha seo a leanas:
Results of (Q)SARs may be used instead of testing when the following conditions are met:
#1939813
vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV) agus a thagann faoi chód AC 30022010 faoi láthair, cibé pacáistíocht atá orthu;
vaccines against SARS-related coronaviruses (SARS-CoV species) currently falling under CN code 30022010, irrespective of their packaging;
#1939944
Substaintí gníomhacha lena n-áirítear máistir-chillbhainc agus cillbhainc infheidhme a úsáidtear chun vacsaíní a mhonarú i gcoinne coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV).
Active substances including master and working cell banks used for the manufacture of vaccines against SARS-related coronaviruses (SARS-CoV species).
#1973303
ciallaíonn ‘paisinéir atá ionfhabhtaithe’ paisinéir a chomhlíonann an critéar saotharlainne maidir le hionfhabhtú SARS-CoV-2;
‘infected passenger’ means a passenger who fulfils the laboratory criterion for SARS-CoV-2 infection;
#1973342
athraitheach den víreas SARS-CoV-2;
variant of SARS-CoV-2 virus;
#1979172
Dá réir sin, maidir leis na srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm chun leathadh SARS-CoV-2 a theorannú, i gcás ina nglacfaidh na Ballstáit le cruthúnas ar vacsaíniú, téarnamh ó ionfhabhtú SARS-CoV-2 nó tástáil le haghaidh SARS-CoV-2 ar mhaithe leis na srianta sin a tharscaoileadh, tá na Ballstáit le glacadh freisin, faoi na coinníollacha céanna, le deimhnithe vacsaínithe i ndáil le vacsaín COVID-19 ar tugadh údarú margaíochta ina leith de bhun Rialachán (CE) Uimh. 726/2005, deimhnithe téarnaimh, nó deimhnithe tástála a léiríonn toradh diúltach arna n-eisiúint ag an Eilvéis i gcomhréir le hOrdú na hEilvéise maidir le Deimhnithe COVID-19.
Accordingly, where Member States accept proof of vaccination, of recovery from SARS-CoV-2 infection or of a test for SARS-CoV-2 infection in order to waive restrictions to free movement put in place to limit the spread of SARS-CoV-2, they are also to accept, under the same conditions, vaccination certificates for a COVID-19 vaccine having been granted marketing authorisation pursuant to Regulation (EC) No 726/2004, certificates of recovery, or test certificates indicating a negative result, issued by Switzerland in accordance with the Swiss COVID-19 Certificate Order.
#1992602
An galar nó oibreán ar ar díríodh: COVID-19 (SARS-CoV-2 nó ceann dá chuid athraitheach)
Disease or agent targeted: COVID-19 (SARS-CoV or one of its variants)
#1992608
"vp": "1119349007" (vacsaín teachtaire NRA SARS-CoV-2)
"vp": "1119349007"(a SARS-CoV-2 mRNA vaccine)
#2043838
Is feiniméan nádúrtha iad sócháin víris SARS-CoV-2 agus féadfar a bheith ag súil go dtarlóidh siad.
Mutations of the SARS-CoV-2 virus are a natural phenomenon and to be expected.
#2055513
Coróinvíreas a bhaineann le Géarshiondróm trom riospráide (coróinvíreas a bhaineann le SARS);
Severe acute respiratory syndrome-related coronavirus (SARS-related coronavirus);
#2074131
Chun an dul chun cinn eolaíoch maidir le paindéim COVID-19 a choinneáil faoi smacht a chur san áireamh, nó chun idir-inoibritheacht le caighdeáin idirnáisiúnta a áirithiú, ba cheart an chumhacht chun gníomhartha a ghlacadh i gcomhréir le hAirteagal 290 CFAE a tharmligean chuig an gCoimisiún chun an Rialachán seo a leasú trí na réimsí sonraí a mhodhnú nó a bhaint, ar réimsí sonraí iad a bheidh le háireamh i nDeimhniú Digiteach COVID AE maidir le céannacht an tsealbhóra, faisnéis faoi vacsaín in aghaidh COVID-19, faoin tástáil le haghaidh ionfhabhtú SARS-CoV-2, faoi ionfhabhtú SARS-CoV-2 a tharla roimhe seo agus faoi mheiteashonraí an deimhnithe, trí réimsí sonraí maidir le céannacht an tsealbhóra, faisnéis faoi vacsaín in aghaidh COVID-19, faoin tástáil le haghaidh ionfhabhtú SARS-CoV-2, faoi ionfhabhtú SARS-CoV-2 a tharla roimhe seo agus faoi mheiteashonraí an deimhnithe a chur leis agus trí leasú a dhéanamh ar an líon laethanta ar ina dhiaidh atá deimhniú téarnaimh le heisiúint.
In order to take into account the scientific progress in containing the COVID-19 pandemic, or to ensure interoperability with international standards, the power to adopt acts in accordance with Article 290 TFEU should be delegated to the Commission to amend this Regulation by modifying or removing the data fields to be included in the EU Digital COVID Certificate regarding the identity of the holder, information about the COVID-19 vaccine, the test for SARS-CoV-2 infection, past SARS-CoV-2 infection and the certificate metadata, by adding data fields regarding information about the COVID-19 vaccine, the test for SARS-CoV-2 infection, past SARS-CoV-2 infection and certificate metadata and by amending the number of days after which a certificate of recovery is to be issued.
#2074234
faisnéis faoi ionfhabhtú SARS-CoV-2 a tharla roimhe seo i ndiaidh toradh tástála dearfaí;
information about past SARS-CoV-2 infection of the holder following a positive test result;
#2074364
an galar nó an t-oibreán ar ar díríodh: COVID-19 (SARS-CoV-2 nó ceann dá chuid athraitheach);
disease or agent targeted: COVID-19 (SARS-CoV-2 or one of its variants);
#2161739
vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV) agus a thagann faoi chód AC 30022010 faoi láthair, cibé pacáistíocht atá orthu;
vaccines against SARS-related coronaviruses (SARS-CoV species) currently falling under CN code 30022010, irrespective of their packaging;
#2161771
substaintí gníomhacha lena n-áirítear máistir-chillbhainc agus cillbhainc infheidhme a úsáidtear chun vacsaíní a mhonarú in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV).
active substances including master and working cell banks used for the manufacture of vaccines against SARS-related coronaviruses (SARS-CoV species).
#2273256
Coróinvíreas a bhaineann le Géarshiondróm trom riospráide (coróinvíreas a bhaineann le SARS);
Severe acute respiratory syndrome-related coronavirus (SARS-related coronavirus);
#2438322
Mar sin féin, tá an víreas SARS-CoV-2 fós ag scaipeadh leis.
However, the SARS-CoV-2 virus is still circulating.
#2550819
Le haghaidh speicis víris SARS-CoV
For SARS-CoV virus species
#2586438
Vacsaíní le haghaidh leigheas an duine (gan vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS a áireamh)
Vaccines for human medicine (excluding vaccines against SARS-related coronaviruses)
#2637492
Tá leanaí de gach aois so-ghabhálach i leith SARS-CoV-2 agus is féidir leo é a tharchur.
Children of all ages are susceptible to and can transmit SARS-CoV-2.
#2697057
Coróinvíreas a bhaineann le Géarshiondróm trom riospráide (coróinvíreas a bhaineann le SARS);
Severe acute respiratory syndrome-related coronavirus (SARS-related coronavirus);
#2822171
Coróinvíreas a bhaineann le Géarshiondróm trom riospráide (coróinvíreas a bhaineann le SARS);
Severe acute respiratory syndrome-related coronavirus (SARS-related coronavirus);
#3020367
Le haghaidh speicis víris SARS-CoV
For SARS-CoV virus species
#1939945
Is éard is “substaintí eile” ann táirgí nó substaintí nach n-úsáidfear chun vacsaíní a mhonarú in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV), ach atá aicmithe faoi na cóid AC chéanna leis na substaintí gníomhacha.
‘Other substances’ are products or substances that are not going to be used to manufacture vaccines against SARS-related coronaviruses (SARS-CoV species), but that are classified under the same CN codes as the active substances.
#1973320
Maidir le sonraí pearsanta a phróiseáil in ardán malartaithe PLF chun críche rianaithe teagmhálaithe SARS-CoV-2 agus chun na críche sin amháin, déanfar na sonraí sin a phróiseáil go dtí an 31 Bealtaine 2022 nó dtí go mbeidh sé dearbhaithe ag Ard-Stiúrthóir na hEagraíochta Domhanda Sláinte, i gcomhréir leis na Rialacháin Sláinte Idirnáisiúnta, go bhfuil deireadh tagtha leis an éigeandáil sláinte poiblí arb ábhar imní ar leibhéal idirnáisiúnta í, éigeandáil atá mar thoradh ar SARS-CoV-2, cibé acu is luaithe.
Processing of personal data in the PLF exchange platform for the sole purpose of SARS-CoV-2 contact tracing shall be performed until 31 May 2022 or until the Director-General of the World Health Organization has declared, in accordance with the International Health Regulations, that the public health emergency of international concern caused by SARS-CoV-2 has ended, whichever is the earliest.
#1977104
Is sampla iad seo a leanas de chóid ar cheart a úsáid ó na córais cód roghnaithe: cód SNOMED CT 1119305005 (vacsaín antaigine SARS-CoV-2), 1119349007 (vacsaín teachtaire RNA SARS-CoV-2) nó J07BX03 (vacsaíní COVID-19).
Examples of codes that should be used from the preferred code systems are the SNOMED CT code 1119305005 (SARS-CoV-2 antigen vaccine), 1119349007 (SARS-CoV-2 mRNA vaccine) or J07BX03 (covid-19 vaccines).
#1979167
Maidir leis na srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm, i gcomhréir le FMOPA, agus staid shonrach na bpobal trasteorann á cur san áireamh, chun leathadh SARS-CoV-2 a theorannú, chuir an Eilvéis in iúl don Choimisiún freisin gur i gcás ina n-éileoidh an Eilvéis cruthúnas ar thástáil ar ionfhabhtú SARS-CoV-2 ar mhaithe leis na srianta sin a tharscaoileadh, go nglacfaidh sí freisin, faoi na coinníollacha céanna, le deimhnithe tástála a léiríonn toradh diúltach arna n-eisiúint ag na Ballstáit i gcomhréir leis an Rialachán seo.
Switzerland further informed the Commission that where Switzerland requires proof of a test for SARS-CoV-2 infection in order to waive the restrictions to free movement put in place, in accordance with the FMOPA, and taking into account the specific situation of cross-border communities, to limit the spread of SARS-CoV-2, it will also accept, under the same conditions, test certificates indicating a negative result issued by Member States in accordance with Regulation (EU) 2021/953.
#1979168
Ina theannta sin, maidir leis na srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm, i gcomhréir le FMOPA, chun leathadh SARS-CoV-2 a theorannú, chuir an Eilvéis in iúl don Choimisiún gur i gcás ina nglacfaidh sí le cruthúnas ar théarnamh ó ionfhabhtú SARS-CoV-2 ar mhaithe leis na srianta sin a tharscaoileadh, go nglacfaidh sí freisin, faoi na coinníollacha céanna, le deimhnithe téarnaimh arna n-eisiúint ag na Ballstáit i gcomhréir le Rialachán (AE) 2021/953.
Switzerland also informed the Commission that where Switzerland accepts proof of recovery from SARS-CoV-2 infection in order to waive restrictions to free movement put in place, in accordance with the FMOPA, to limit the spread of SARS-CoV-2, it will accept, under the same conditions, certificates of recovery issued by Member States in accordance with Regulation (EU) 2021/953.
#1992443
Is sampla iad seo a leanas de chóid a úsáidfear ó na córais cód roghnaithe: cód SNOMED CT 1119305005 (vacsaín antaigine SARS-CoV-2), 1119349007 (vacsaín teachtaire RNA SARS-CoV-2) nó J07BX03 (vacsaíní COVID-19).
Examples of codes that shall be used from the preferred code systems are the SNOMED CT code 1119305005 (SARS-CoV-2 antigen vaccine), 1119349007 (SARS-CoV-2 mRNA vaccine) or J07BX03 (covid-19 vaccines).
#2073953
Chun leathadh SARS-CoV-2 a theorannú, tá roinnt beart glactha ag na Ballstáit, bearta a raibh tionchar acu ar shaoránaigh den Aontas agus a gceart á fheidhmiú acu gluaiseacht agus cónaí faoi shaoirse ar chríoch na mBallstát, amhail srianta ar dhul isteach nó ceanglais ar thaistealaithe trasteorann coraintín nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh.
To limit the spread of SARS-CoV-2, the Member States have adopted some measures which have had an impact on the exercise by Union citizens of their right to move and reside freely within the territory of the Member States, such as entry restrictions or requirements for cross-border travellers to undergo quarantine or self-isolation or to be tested for SARS-CoV-2 infection.
#2073954
An 13 Deireadh Fómhair 2020, ghlac an Chomhairle Moladh (AE) 2020/1475, lenar tugadh isteach cur chuige comhordaithe i leith an tsaorghluaiseacht a shrianadh mar fhreagairt ar phaindéim COVID-19 sna príomhréimsí seo a leanas: critéir chomhchoiteanna agus tairseacha comhchoiteanna a chur i bhfeidhm, agus cinneadh á dhéanamh ar cheart srianta ar an tsaorghluaiseacht a thabhairt isteach, mapáil ar limistéir riosca thras-seoladh SARS-CoV-2 bunaithe ar chód dathanna comhaontaithe agus cur chuige comhordaithe i leith aon bhearta iomchuí a d’fhéadfaí a chur i bhfeidhm maidir le daoine atá ag taisteal go dtí limistéir riosca nó uathu, ag brath ar leibhéal an riosca a bhaineann le tras-seoladh SARS-CoV-2 sna limistéir sin.
On 13 October 2020, the Council adopted Recommendation (EU) 2020/1475, which introduced a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic in the following key areas: the application of common criteria and thresholds when deciding whether to introduce restrictions to free movement, a mapping of risk areas of SARS-CoV-2 transmission based on an agreed colour code and a coordinated approach to any appropriate measures which could be applied to persons travelling to or from risk areas, depending on the level of risk of SARS-CoV-2 transmission in those areas.
#2074049
I gcás ina nglacfaidh Ballstáit le cruthúnas ar vacsaíniú chun srianta ar an tsaorghluaiseacht a cuireadh i bhfeidhm, i gcomhréir le dlí an Aontais chun teorainn a chur le leathadh SARS-CoV-2, a tharscaoileadh, amhail ceanglas chun coraintín nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh, ba cheart a cheangal orthu glacadh le deimhnithe vacsaínithe arna n-eisiúint ag Ballstáit eile i gcomhréir leis an Rialachán seo faoi na coinníollacha céanna.
Where Member States accept proof of vaccination in order to waive restrictions to free movement put in place, in accordance with Union law to limit the spread of SARS-CoV-2, such as a requirement to undergo quarantine or self-isolation or to be tested for SARS-CoV-2 infection, they should be required to accept, under the same conditions, vaccination certificates issued by other Member States in accordance with this Regulation.
#2074086
Ballstáit a éilíonn cruthúnas ar thástáil le haghaidh ionfhabhtú SARS-CoV-2 chun na srianta ar an tsaorghluaiseacht a cuireadh i bhfeidhm chun teorainn a chur le leathadh SARS-CoV-2 a tharscaoileadh, ba cheart do na Ballstáit sin glacadh le deimhnithe tástála COVID-19 lena léirítear toradh diúltach arna n-eisiúint ag na Ballstáit i gcomhréir leis an Rialachán seo faoi na coinníollacha céanna.
COVID-19 test certificates indicating a negative result issued by Member States in accordance with this Regulation should be accepted, under the same conditions, by Member States requiring proof of a test for SARS-CoV-2 infection in order to waive the restrictions to free movement put in place to limit the spread of SARS-CoV-2.
#2074092
De réir ECDC, tá sé léirithe le fianaise a cuireadh ar fáil le déanaí, cé gur féidir SARS-CoV-2 inmharthana a scoitheadh idir 10 agus 20 lá tar éis thús na siomptóm, gur mhainnigh staidéir eipidéimeolaíochta a léiriú go cinntitheach gur féidir SARS-CoV-2 a thras-sheoladh ar aghaidh tar éis 10 lá.
According to the ECDC, recent evidence shows that despite shedding of viable SARS-CoV-2 between ten and twenty days from the onset of symptoms, convincing epidemiological studies have failed to show onward SARS-CoV-2 transmission after ten days.
#2074095
I gcás ina nglacfaidh Ballstáit le cruthúnas ar théarnamh chun srianta ar an tsaorghluaiseacht a cuireadh i bhfeidhm, i gcomhréir le dlí an Aontais, chun teorainn a chur le leathadh SARS-CoV-2 a tharscaoileadh, amhail ceanglais chun coraintín nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh, ba cheart a cheangal orthu glacadh, faoi na coinníollacha céanna, le deimhnithe téarnaimh ó COVID-19 arna n-eisiúint ag Ballstáit eile i gcomhréir leis an Rialachán seo.
Where Member States accept proof of recovery in order to waive restrictions to free movement put in place, in accordance with Union law, to limit the spread of SARS-CoV-2, such as a requirement to undergo quarantine or self-isolation or to be tested for SARS-CoV-2 infection, they should be required to accept, under the same conditions, certificates of recovery from COVID-19 issued by other Member States in accordance with this Regulation.
#2074098
Chun go mbeidh sé ar chumas an Choimisiúin teacht ar chomhsheasamh go mear, ba cheart dó a bheith in ann a iarraidh ar an gCoiste Slándála Sláinte, ar ECDC nó ar EMA treoir a eisiúint maidir leis an bhfianaise eolaíoch atá ar fáil maidir le hiarmhairtí teagmhas leighis a dhoiciméadaítear i ndeimhnithe arna mbunú i gcomhréir leis an Rialachán seo, lena n-áirítear éifeachtacht agus fad thréimhse na himdhíonachta arna tabhairt le vacsaíní in aghaidh COVID-19, cibé acu a chuireann nó nach gcuireann vacsaíní cosc ar ionfhabhtú aisiomptómach agus tras-seoladh SARS-CoV-2, staid na ndaoine atá téarnaithe ó COVID-19, agus an tionchar atá ag athraithigh SARS-CoV-2 nua ar dhaoine atá vacsaínithe nó ionfhabhtaithe cheana.
To be able to obtain a common position quickly, the Commission should be able to ask the Health Security Committee, the ECDC or EMA to issue guidance on the available scientific evidence on the effects of medical events documented in the certificates established in accordance with this Regulation, including the effectiveness and duration of the immunity conferred by COVID-19 vaccines, whether vaccines prevent asymptomatic infection and SARS-CoV-2 transmission, the situation of people having recovered from COVID-19, and the impacts of the new SARS-CoV-2 variants on people who have been vaccinated or already infected.
#2074159
ciallaíonn “tástáil antasubstainte” tástáil saotharlainn-bhunaithe arb é is aidhm léi a bhrath an bhfuil antasubstaintí i gcoinne SARS-CoV-2 forbartha ag duine, rud a léiríonn gur nochtadh an sealbhóir do SARS-CoV-2 agus gur fhorbair sé nó sí antasubstaintí, is cuma cé acu an raibh siomptóim ag an duine sin nó nach raibh;
‘antibody test’ means a laboratory-based test aiming to detect if a person has developed antibodies against SARS-CoV-2, thus indicating that the holder has been exposed to SARS-CoV-2 and has developed antibodies, regardless of whether that person was symptomatic;
#2074227
Srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm, i gcomhréir le dlí an Aontais agus staid shonrach na bpobal trasteorann á cur san áireamh, chun leathadh COVID-19 a theorannú, i gcás ina n-éileoidh na Ballstáit cruthúnas ar thástáil le haghaidh ionfhabhtú SARS-CoV-2 chun na srianta sin a tharscaoileadh, glacfaidh siad freisin, faoi na coinníollacha céanna, le deimhnithe tástála lena léirítear toradh diúltach arna n-eisiúint ag Ballstáit eile i gcomhréir leis an Rialachán seo.
Where Member States require proof of a test for SARS-CoV-2 infection in order to waive the restrictions to free movement put in place, in accordance with Union law and taking into account the specific situation of cross-border communities, to limit the spread of SARS-CoV-2, they shall also accept, under the same conditions, test certificates indicating a negative result issued by other Member States in accordance with this Regulation.
#2074243
Srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm, i gcomhréir le dlí an Aontais, chun leathadh COVID-19 a theorannú, i gcás ina nglacfaidh na Ballstáit le cruthúnas téarnaimh ó ionfhabhtú SARS-CoV-2 chun na srianta sin a tharscaoileadh, glacfaidh siad, faoi na coinníollacha céanna, le deimhnithe téarnaimh arna n-eisiúint ag Ballstáit eile i gcomhréir leis an Rialachán seo.
Where Member States accept proof of recovery from SARS-CoV-2 infection in order to waive restrictions to free movement put in place, in accordance with Union law, to limit the spread of SARS-CoV-2, they shall accept, under the same conditions, certificates of recovery issued by other Member States in accordance with this Regulation.
#2074286
I gcás ina gceanglóidh Ballstát, i gcomhréir le dlí an Aontais, ar shealbhóirí na ndeimhnithe dá dtagraítear in Airteagal 3 tabhairt faoi choraintín, féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 tar éis dóibh dul isteach ina chríoch, nó i gcás ina bhforchuireann sé srianta eile ar shealbhóirí deimhnithe den sórt sin toisc, mar shampla, go dtéann an staid eipidéimeolaíoch i mBallstát nó i réigiún laistigh de Bhallstát in olcas go tapa, go háirithe mar thoradh ar athraitheach SARS-CoV-2 is ábhar imní nó suime, cuirfidh sé an Coimisiún agus na Ballstáit eile ar an eolas dá réir sin, 48 n-uair an chloig sula dtabharfar srianta nua den sort sin isteach, más féidir.
Where a Member State requires, in accordance with Union law, holders of the certificates referred to in Article 3(1) to undergo, after entry into its territory, quarantine or self-isolation or to be tested for SARS-CoV-2 infection, or if it imposes other restrictions on the holders of such certificates because, for example, the epidemiological situation in a Member State or in a region within a Member State worsens quickly, in particular as a result of a SARS-CoV-2 variant of concern or interest, it shall inform the Commission and the other Member States accordingly, if possible 48 hours in advance of the introduction of such new restrictions.
#2074402
Chun leathadh SARS-CoV-2 a theorannú, tá roinnt beart glactha ag na Ballstáit, bearta a raibh tionchar ag roinnt acu ar thaisteal chuig agus laistigh de chríoch na mBallstát, amhail srianta ar dhul isteach nó ceanglais ar thaistealaithe trasteorann coraintín nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh.
To limit the spread of SARS-CoV-2, the Member States have adopted some measures which have had an impact on travel to and within the territory of the Member States, such as entry restrictions or requirements for cross-border travellers to undergo quarantine or self-isolation or to be tested for SARS-CoV-2 infection.
#2074410
I gcás ina nglacfaidh Ballstáit le cruthúnas ar vacsaíniú chun srianta taistil a cuireadh i bhfeidhm a tharscaoileadh, i gcomhréir le dlí an Aontais, chun teorainn a chur le leathadh SARS-CoV-2, amhail ceanglas chun coraintín, féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh, ba cheart a cheangal orthu, faoi na coinníollacha céanna, glacadh le deimhnithe vacsaínithe arna n-eisiúint ag Ballstáit eile i gcomhréir le Rialachán (AE) 2021/953 ó Pharlaimint na hEorpa agus ón gComhairle.
Where Member States accept proof of vaccination in order to waive travel restrictions put in place, in accordance with Union law to limit the spread of SARS-CoV-2, such as a requirement to undergo quarantine or self-isolation or to be tested for SARS- CoV-2 infection, they should be required to accept, under the same conditions, vaccination certificates issued by other Member States in accordance with Regulation (EU) 2021/953. of the European Parliament and of the Council.
#2161732
Faoi na cúinsí atá ann faoi láthair, sin agus staid an tsoláthair, maidir leis an gceanglas údarú onnmhairiúcháin a thabhairt ar aird le haghaidh onnmhairiúcháin vacsaíní in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV) agus substaintí gníomhacha, lena n-áirítear máistir-chillbhainc agus cillbhainc infheidhme a úsáidtear chun na vacsaíní sin a mhonarú, is éard a mheas an Coimisiún nach gá an ceanglas sin a chur i bhfeidhm i ndiaidh an 31 Nollaig 2021.
Under the current circumstances and situation of supply, the Commission considered the application of the requirement to produce an export authorisation for the exports of vaccines against SARS-related coronaviruses (SARS-CoV species) and active substances, including master and working cell banks used for the manufacture of such vaccines, after 31 December 2021, not required.
#2161772
is éard is “substaintí eile” ann táirgí nó substaintí nach n-úsáidfear chun vacsaíní a mhonarú in aghaidh coróinvíris a bhfuil gaol acu le SARS (speicis SARS-CoV), ach atá aicmithe faoi na cóid AC chéanna leis na substaintí gníomhacha.
‘Other substances’ are products or substances that are not going to be used to manufacture vaccines against SARS-related coronaviruses (SARS-CoV species), but that are classified under the same CN codes as the active substances.
#2265816
Léiríodh leis na hathraithigh ‘Alpha’, ‘Delta’ agus ‘Omicron’ SARS-CoV-2, arb é an tríú ceann an t-athraitheach is coitianta anois san Aontas, an drochthionchar is féidir a bheith ag athraithigh nua SARS-CoV-2 ar an staid eipidéimeolaíoch.
The SARS-CoV-2 variants ‘Alpha’, ‘Delta’ and ‘Omicron’, the latter in the process of becoming the dominant variant within the Union, have demonstrated the negative impact new SARS-CoV-2 variants can have on the epidemiological situation.